aTYR PHARMA INC Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
aTYR PHARMA INC (ATYR) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $48.59 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-07
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $48.59M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $57.74M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $67.29M.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $80.04M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $48.59M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $57.74M 10-Q · filed 2026-08-07 |
| 2025-12-31 | $67.29M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $80.04M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $74.66M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $74.86M 10-Q · filed 2026-08-07 |
| 2024-12-31 | $69.83M 10-Q · filed 2026-08-07 |
| 2024-09-30 | $65.14M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $81.42M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $84.28M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $90.47M 10-K · filed 2026-03-05 |
| 2023-09-30 | $98.20M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $106.05M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $109.70M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $71.28M 10-K · filed 2026-03-05 |
| 2022-09-30 | $77.01M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $86.46M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $98.37M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $109.13M 10-K · filed 2025-03-13 |
| 2021-09-30 | $117.44M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $40.80M 10-Q · filed 2022-11-14 |
| 2021-03-31 | $49.53M 10-Q · filed 2022-11-14 |
| 2020-12-31 | $31.48M 10-K · filed 2024-03-14 |
| 2020-09-30 | $32.00M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $35.94M 10-Q · filed 2021-11-12 |
| 2020-03-31 | $41.97M 10-Q · filed 2021-11-12 |
| 2019-12-31 | $21.03M 10-K · filed 2023-03-14 |
| 2018-12-31 | $33.65M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |